ATLAS ACS-TIMI 46

ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes.

MAIN RESULTS:
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Lancet. 2009 Jul 4;374(9683):29-38

PRESENTATIONS

TIMI 46 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan, AHA 2019)

OTHER PUBLICATIONS

Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. J Thromb Thrombolysis. 2014 Apr;37(3):310-6.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation 2021;143:685-695.